Transcripta Bio Raises $24M for Autism, FSHD Trials

Transcripta Bio, an AI-driven drug discovery company focused on neurological and neuromuscular diseases, has raised $24 million since its Series A round. The funding will support IND-enabling studies across its pipeline and clinical preparation for its Autism Spectrum Disorder (ASD) and Facioscapulohumeral Muscular Dystrophy (FSHD) programs.

Mayo Clinic and Omnimed joined existing investors JAZZ Venture Partners, BlueYard Capital, and a group of life sciences family offices in the round. The company's pipeline includes four programs: Myotonic Dystrophy, FSHD, ASD, and Huntington's Disease. The company is based in Palo Alto.